Krystal Biotech Inc (KRYS) Stock Analysis

Krystal Biotech Inc (KRYS) is a publicly traded company in the HEALTHCARE sector. It trades at $293.21, carries a market capitalization of $8.79B, a price-to-earnings ratio of 39.85. This page summarizes the public market data, fundamentals, and frequently asked questions for KRYS, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

Market Sentiment

Krystal Biotech Inc currently has a Bullish sentiment score of 0.25.

About Krystal Biotech Inc

Krystal Biotech, Inc. is a clinical-stage biotechnology company headquartered in Pittsburgh, Pennsylvania, dedicated to developing redosable gene therapies specifically for rare diseases. Leveraging its proprietary platform and robust pipeline, Krystal Biotech aims to deliver sustained therapeutic solutions that significantly improve patient outcomes for genetic disorders. The company's innovative strategies and focused commitment to addressing critical unmet medical needs underscore its pote...

GNG Research Analysis

GNG Research scores Krystal Biotech Inc (KRYS) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for KRYS.

Frequently Asked Questions

Does KRYS pay dividends?

Krystal Biotech Inc (KRYS) does not currently pay a regular dividend.

What is KRYS's P/E ratio?

Krystal Biotech Inc has a price-to-earnings (P/E) ratio of 39.85.

What is KRYS's market cap?

Krystal Biotech Inc (KRYS) has a market capitalization of $8.79B with a current stock price of $293.21.